CCI4EU - Cost of health care and drugs
MATERIALS AVAILABLE
CCI4EU - Cost of health care and drugs
MATERIALS AVAILABLE

Chairs
: Mark Lawler, UK & Wim van Harten, NL
To access the on-demand materials (after the live streaming), participants must register to the course, login to the e-ESO platform and click on the play buttons inside the course programme.
Introduction to the pre-recorded part of the course
Cost of drugs and negotiation with pharma
The economic burden of cancer
Mark Lawler (UK)Cost of Cancers (UK)
Katie Spencer (UK)Cost of Cancer Medicines across EU
Nora Franzen (NL)Health Technology Assessment alongside the translation research process (VR)
Valesca Retel (NL)How can we measure the clinical performance and value of drugs after adoption?
Peter S Hall (UK)Financial toxicity
Financial toxicity (use of measurement instruments)
Rachel Eckford (DE)Socio-economic outcomes of Adolecent and Young Adult (AYA) cancer patients
Silvie Janssen (NL)The cost of diagnostics
Costs, budget impact and/or cost effectiveness of sequencing
Astrid Kramer (NL)Cost of testing vs cost of not testing
Peter Keeling (UK)Health economics and diagnostics/precision medicine
Raymond Henderson (UK)Costs and cost effectiveness of early detection in head and neck cancer
Lionel Perrier (FR)Regulatory part
How countries decide via agencies on coverage
Martina Garau (UK)How innovation gets to the patients
Wim H. Van Harten (NL)Coverage with evidence development programs
Joost Verbeek (NL)LIVE STREAMING
Introduction & Welcome to the live course
Live Presentations & Discussions (part 1)
Comparative overview of costs and infrastructure for cancer treatement in (especially EU) OECD countries
Caroline Berchet (FR)Value based health care and use of PROMs in the clinic
Rita Silva Calisto (PT)Financial Sustainability
Ajay Aggarwal (UK)Discussion
Live Presentations & Discussions (part 2)
Financial Toxicity: Socio-economic impact
Wim H. Van Harten (NL)Personal Story Advocate
Marianne Massart (LU)Right to be Forgotten
Mark Lawler (UK) Francoise Meunier (BE)Discussion
Live Cases & Discussions
Deploying data to influence cancer policy
Mark Lawler (UK)Roundtable and Discussion
Diagnostics case
Valesca Retel (NL)Roundtable and discussion
Take home message and closing remarks
End of the course
Ajay Aggarwal
London School of Hygiene and Tropical Medicine, Department of Health Services Research and Policy, London, UK
Astrid Kramer
, , ,
Caroline Berchet
Organization for Economic Co-operation and Development (OECD), Healh Policy, Paris Cedex 16, FR
Francoise Meunier
1050 brussels, BE
Joost Verbeek
, , ,
Katie Spencer
, , ,
Lionel Perrier
, , ,
Marianne Massart
, , ,
Mark Lawler
Queens University Hospital, Centre for Cancer Research and Cell Biology, Belfast, UK
Martina Garau
, , ,
Nora Franzen
, , ,
Peter Keeling
, , ,
Peter S Hall
, , ,
Rachel Eckford
German Cancer Research Center (DKFZ), Foundation under Public Law, Heidelberg, DE
Raymond Henderson
, , ,
Rita Silva Calisto
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E., ORLab, Porto, PT
Silvie Janssen
, , ,
Valesca Retel
, , ,
Wim H. Van Harten
Rijnstate Ziekenhuis, Chairman Board of Directors, Arnhem, NL
